Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

At issue was a battle over patents for Truvada and a newer, upgraded version called Descovy — two highly effective and lucrative medications — as well as the role played by the federal ...

Gilead has maintained that it fully compensated the CDC for its contributions to the development of Truvada for PrEP while the government had argued that Gilead did not properly acknowledge or ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

LILY Phillips has revealed she is taking HIV protection drug PrEP ahead of her next sex challenge. But viewers have claimed ...